Radical cystectomy
Radical cystectomy is a medical procedure with 33 clinical trials. Currently 11 active trials ongoing. Historical success rate of 57.1%.
Success Metrics
Based on 8 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
17
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
47.1%
8 of 17 finished
52.9%
9 ended early
11
trials recruiting
33
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial
Clinical Trials (33)
A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial
A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy
Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma
Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy
Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder
Post-surgical Delirium in Patients Undergoing Radical Cystectomy.
Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy
Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
Robotic Radical Cystectomy Outcomes
Study Comparing Open Radical Cystectomy With Robot-assisted Cystectomy in Patients With Bladder Cancer
Drug Details
- Intervention Type
- PROCEDURE
- Total Trials
- 33